NFATC2IP

Across TCGA pan-cancer cohorts, NFATC2IP mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NFATC2IP data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NFATC2IP mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NFATC2IP expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, HNSC, and LSCC are the cancer types where NFATC2IP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.893	0.721	.007	25	view →
HNSC	DFS	Median	IV	0.468	0.789	.003	20	view →
LSCC	DFS	Median	II,III,IV	0.828	0.543	.005	18	view →
LUAD	DFS	Median	II,III,IV	0.883	0.245	.005	14	view →
PDAC	DFS	Tertile	All	0.882	0.655	.022	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NFATC2IP–CCRCC (DFS)

Open the CCRCC breakdown →